Home › Funds › Defilade Capital Management, L.P. › PTCT
Defilade Capital Management, L.P. position in PTCT
PTC THERAPEUTICS INC · Health Care
Defilade Capital Management, L.P. reported holding 433,699 shares of PTCT (PTC THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$35.4M, representing 4.74% of its reported portfolio and ranking #5 among its reported holdings. Defilade Capital Management, L.P. has disclosed PTCT holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Defilade Capital Management, L.P.'s PTCT position evolved
Defilade Capital Management, L.P. first disclosed a stake in PTCT in Q1 2026 at 376,165 shares (US$25.6M). The position peaked in Q2 2026 at 433,699 shares, worth US$35.4M. Across 2 filings, Defilade Capital Management, L.P. increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 433,699 shares valued at US$35.4M — an increase of 57,534 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 376.17K | $25.63M | New |
| Q2 2026 | 433.70K | $35.38M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PTCT and 13F data
PTCT (PTC THERAPEUTICS INC) is a Health Care company. 54 other funds we track also report a position in PTCT — the largest reported positions include RTW INVESTMENTS, LP (US$631.9M), TORONTO DOMINION BANK (US$176.7M), WESTFIELD CAPITAL MANAGEMENT CO LP (US$159.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PTCT
- RTW INVESTMENTS, LP 7.75M sh · $631.88M · Q2 2026
- TORONTO DOMINION BANK 2.17M sh · $176.67M · Q2 2026
- WESTFIELD CAPITAL MANAGEMENT CO LP 1.96M sh · $159.56M · Q2 2026
- Hood River Capital Management LLC 1.74M sh · $141.82M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 1.50M sh · $122.36M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 1.44M sh · $117.47M · Q2 2026
- Jefferies Financial Group Inc. 1.36M sh · $110.69M · Q2 2026
- Blue Sparrow, LLC /DE 1.05M sh · $85.71M · Q2 2026
- Palo Alto Investors LP 918.85K sh · $74.95M · Q2 2026
- ARMISTICE CAPITAL, LLC 660.00K sh · $53.84M · Q2 2026
- Parkman Healthcare Partners LLC 435.69K sh · $35.54M · Q2 2026
More on Defilade Capital Management, L.P.
FAQ
How long has Defilade Capital Management, L.P. held PTCT?
Defilade Capital Management, L.P. has disclosed PTCT holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Defilade Capital Management, L.P.'s current position in PTCT?
As of Q2 2026, Defilade Capital Management, L.P. holds 433.70K shares of PTCT (PTC THERAPEUTICS INC), valued at $35.38M, representing 4.74% of its reported portfolio and ranking #5.
Has Defilade Capital Management, L.P. been buying or selling PTCT?
In the latest 13F filing (Q2 2026), Defilade Capital Management, L.P. increased its position in PTCT. The position peaked in Q2 2026 at 433.70K shares.
Which other funds hold PTCT?
Other major institutional holders of PTCT include RTW INVESTMENTS, LP, TORONTO DOMINION BANK, WESTFIELD CAPITAL MANAGEMENT CO LP, among 54 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.